-
Media Release
Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month
-
Media Release
Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month
-
Media Release
Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community
-
Media Release
Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community
-
Media Release
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
-
Media Release
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
-
Media Release
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
-
Media Release
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
-
Media Release
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-
Media Release
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-
Media Release
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
-
Media Release
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer